HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD Simplifies, Lowers Fees For Disclosure Challenges In SWIFT Ad Claim Reviews

Executive Summary

National Advertising Division streamlined the process for submitting SWIFT challenges about disclosure claims and lowered the filing fee for the challenges. Growing use of testimonials, “influencer” marketing prompted change.

You may also be interested in...



PLx Pharma Irritated By Industry Self-Regulation Group’s Findings On Vazalore GI Comfort Claim

PLx disagrees with National Advertising Division’s recommendations following review on Bayer’s challenge of TV commercial and will appeal findings to National Advertising Review Board. NAD attorneys thank PLx’s “ voluntary participation” in SWIFT review but PLx makes clear it didn’t agree to a SWIFT process.

FTC ‘Dark Patterns' Enforcement Policy Darkens Public Input On Rule, Commissioner Wilson Argues

Wilson’s dissenting statement isn’t first time she's disagreed with Democrat majority on the five-seat commission after four years of a Republican majority. Her statement made clear her argument the commission has over-stepped its authorities more than once.

FTC Aims At Deceptive Endorsements: Beauty, Health Firms Can Assure They're Not Targets

US FTC sends notices to more than 700 companies about penalties they will face if they use deceptive endorsements and testimonials to promote their products. Industry experts discuss impact of surprising action and cautions to take in teaming up with influencers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel